TY - JOUR
T1 - Effects of nisoldipine treatment on plasma lipoproteins
AU - Perani, G.
AU - Martignoni, A.
AU - Muggia, C.
AU - Bongarzoni, A.
AU - Testa, F.
AU - Radaelli, A.
AU - Borgnino, C.
AU - Finardi, G.
PY - 1987
Y1 - 1987
N2 - The effects of the new calcium antagonist nisoldipine on plasma lipoproteins were assessed in a group of 15 normolipidic hypertensive patients. After a two-week washout period, the patients were given 5- to 20-mg nisoldipine orally for four weeks. Nisoldipine treatment was associated with a significant increase in both high-density lipoprotein (HDL)-cholesterol (+ 14%, P <0.01), largely dependent on the increase in the denser subfraction HDL3 (+ 13%, P <0.005), and apoprotein A (+ 12%, P <0.05). Total and low-density lipoprotein (LDL)-cholesterol, triglycerides, and apoprotein B did not change. Nisoldipine treatment appears to induce changes in the lipoprotein profile that are favorable to the cardiovascular risk in hypertensive patients.
AB - The effects of the new calcium antagonist nisoldipine on plasma lipoproteins were assessed in a group of 15 normolipidic hypertensive patients. After a two-week washout period, the patients were given 5- to 20-mg nisoldipine orally for four weeks. Nisoldipine treatment was associated with a significant increase in both high-density lipoprotein (HDL)-cholesterol (+ 14%, P <0.01), largely dependent on the increase in the denser subfraction HDL3 (+ 13%, P <0.005), and apoprotein A (+ 12%, P <0.05). Total and low-density lipoprotein (LDL)-cholesterol, triglycerides, and apoprotein B did not change. Nisoldipine treatment appears to induce changes in the lipoprotein profile that are favorable to the cardiovascular risk in hypertensive patients.
UR - http://www.scopus.com/inward/record.url?scp=0023571576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023571576&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0023571576
VL - 42
SP - 601
EP - 606
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 4
ER -